Any current/future new fundraising through debt or equity?

Chemcon Specialty Chemicals Limited has ongoing capital expenditure projects, specifically plants P8 and P9, funded by IPO proceeds and internal accruals. Rs. 25 Crores of capex has already been incurred, with further expenditure ongoing for these new plants. No explicit mention of any new or future fundraising through additional debt or equity beyond the IPO proceeds used for current expansions. The company is focusing on capacity expansions, new product commercialization, and increasing production volumes funded by internal resources and the IPO. No clear statement on plans for further capit

Any current/future capex/capital investment/strategic investment?

Ongoing capital expenditure on plants P8 and P9, funded partly by IPO proceeds and internal accruals; about Rs. 25 Crores incurred so far. P8 plant expected to be commercialized in approximately 5 to 5.5 months, and P9 plant around 12 months from the call date (Feb 2021). The new multipurpose plants (P8 & P9) will support existing products and enable manufacturing of new products such as 4-chlorobutyryl chloride, 2,5 DHT, and expanded CMIC capacity. Total volumetric reactor capacity after expansion will be ~625 kl. Future capex beyond P8 & P9 not specifically detailed but focus remains on cont

Future growth expectations in sales/revenue/volumes?

Targeted growth of around 15% to 20% in HMDS volumes (Page 11). Around 30% growth expected in CMIC volumes, plus addition of new products (Page 11). Plan to increase production capacities and real-time production by 30% in FY2022 (Page 16). New products like 4-chlorobutyryl chloride and 2,5-DHT expected to contribute Rs. 75-100 Crores revenue each with less than 1-year capex payback period (Pages 12, 5-6). Expansion plants P8 and P9 to commercialize new and existing products, with P8 commercializing in ~5-5.5 months and P9 in ~12 months (Pages 5, 8). Bromide volumes expected to recov

Future growth expectations in earnings/operating earnings/profits/EPS?

Targeted growth of around 15% to 20% in HMDS segment and around 30% in CMIC segment over the next few years. New product additions expected to contribute significantly, with capex payback period less than a year and expected topline of Rs. 75-100 Crores per new product. Capacity expansions (plants P8 and P9) underway, with P8 commercializing in approx. 5-5.5 months and P9 in about 12 months, expected to support growth. Volume growth and new product commercialization are key growth drivers. Margins expected to remain stable with improvements from higher volumes and cost efficiencies. Overall lo

Current/ Expected Orderbook/ Pending Orders?

The bromide business is showing signs of recovery with pending orders and clearances initiating dispatches and supplies. Kamal Aggarwal mentioned that about 60% to 70% of the bromide volume pending will be recovered in the current quarter. The company is getting volume requirements and anticipates business recovery in the bromide segment. New products like 4-chlorobutyryl chloride and 2,5 DHT have started commercial supplies, indicating an expanding order book. Expansion projects (P8 and P9) are underway, expected to enhance production capacity and order fulfillment ability within 5-12 months.

IN US

Sale is live|00:00:00left today

Chemcon Speciality Chemicals LtdQ4 FY22Chemicals & Petrochemicals

Chemcon Speciality Chemicals Ltd Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹188P/E: 28.3Market Cap: ₹599 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Targeted growth of around 15% to 20% in HMDS volumes (Page 11).
→Around 30% growth expected in CMIC volumes, plus addition of new products (Page 11).
→Plan to increase production capacities and real-time production by 30% in FY2022 (Page 16).
→New products like 4-chlorobutyryl chloride and 2,5-DHT expected to contribute Rs. 75-100 Crores revenue each with less than 1-year capex payback period (Pages 12, 5-6).
→Expansion plants P8 and P9 to commercialize new and existing products, with P8 commercializing in ~5-5.5 months and P9 in ~12 months (Pages 5, 8).
→Bromide volumes expected to recover to 60-70% of earlier quarterly levels (~1 million kg) (Page 16).
→Focus on penetrating new clients, new geographic markets, and ongoing cost efficiencies as growth levers (Page 16).
→Innovation pipeline includes adding at least 2 new products annually (Page 12).

Margin guidance

Category 3

→Targeted growth of around 15% to 20% in HMDS segment and around 30% in CMIC segment over the next few years.
→New product additions expected to contribute significantly, with capex payback period less than a year and expected topline of Rs. 75-100 Crores per new product.
→Capacity expansions (plants P8 and P9) underway, with P8 commercializing in approx. 5-5.5 months and P9 in about 12 months, expected to support growth.
→Volume growth and new product commercialization are key growth drivers.
→Margins expected to remain stable with improvements from higher volumes and cost efficiencies.
→Overall long-term vision to multiply current market value several times with leadership in products and continuous innovation.
→Working to reduce client concentration through exports, aiming to expand geographic reach and market share.
→Expect overall business growth supported by increasing demand in pharma chemicals and oil well completion sectors.

3 more insights locked — sign up free to unlock

Fundraise plans

→Chemcon Specialty Chemicals Limited has ongoing capital expenditure projects, specifically plants P8 and P9, funded by IPO proceeds and internal accruals.
→Rs. 25 Crores of capex has already been incurred, with further expenditure ongoing for these new plants.
→No explicit mention of any new or future fundraising through additional debt or equity beyond the IPO proceeds used for current expansions.
→The company is focusing on capacity expansions, new product commercialization, and increasing production volumes funded by internal resources and the IPO.
→No clear statement on plans for further capital raising was provided in the call.

Order book

→The bromide business is showing signs of recovery with pending orders and clearances initiating dispatches and supplies.
→Kamal Aggarwal mentioned that about 60% to 70% of the bromide volume pending will be recovered in the current quarter.
→The company is getting volume requirements and anticipates business recovery in the bromide segment.
→New products like 4-chlorobutyryl chloride and 2,5 DHT have started commercial supplies, indicating an expanding order book.
→Expansion projects (P8 and P9) are underway, expected to enhance production capacity and order fulfillment ability within 5-12 months.
→The working capital on receivables is Rs. 85 Crores as of nine months FY2021, reflecting business carried out and orders in process.

Capex plans

Yes

→Ongoing capital expenditure on plants P8 and P9, funded partly by IPO proceeds and internal accruals; about Rs. 25 Crores incurred so far.
→P8 plant expected to be commercialized in approximately 5 to 5.5 months, and P9 plant around 12 months from the call date (Feb 2021).
→The new multipurpose plants (P8 & P9) will support existing products and enable manufacturing of new products such as 4-chlorobutyryl chloride, 2,5 DHT, and expanded CMIC capacity.
→Total volumetric reactor capacity after expansion will be ~625 kl.
→Future capex beyond P8 & P9 not specifically detailed but focus remains on continuous product additions and capacity expansions.
→New product additions target revenue sizes of Rs. 75-100 Crores with a payback period of under one year.
→Strategic emphasis on penetrating new clients, new geographic markets, and ongoing cost efficiencies to drive growth.

How does Chemcon Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Chemcon Speciality Chemicals Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Chemcon Speciality Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio